Quarterly report pursuant to Section 13 or 15(d)

7. Stockholders' Equity (Details Narrative)

v3.5.0.2
7. Stockholders' Equity (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Dividends earned $ 0 $ 797,344 $ 0 $ 1,320,394  
Stock issued for services, value     9,310    
Unrecognized compensation cost 300,000   $ 300,000    
Unrecognized compensation cost amortization period     1 year 4 months 10 days    
Options Granted [Member]          
Share based compensation expense 400,000   $ 400,000    
Medytox [Member] | Common stock to employees and consultants [Member]          
Share based compensation expense       2,800,000  
Medytox [Member] | Outstanding options [Member]          
Share based compensation expense       269,000  
Warrant Exercises [Member]          
Stock issued for warrants exercised     43,809    
Previously converted preferred stock [Member]          
Shares issued in adjustment of prior conversion of preferred stock, shares     50,606    
Previously issued to employee [Member]          
Stock cancelled, shares     40,964    
Consultant [Member]          
Stock issued for services, shares issued     13,300    
Stock issued for services, value     $ 9,310    
Medytox Series B Preferred Stock [Member]          
Dividends earned       $ 1,300,000  
Accrued dividends $ 2,100,000   $ 2,100,000   $ 1,700,000
Series C Preferred Stock [Member]          
Preferred stock converted into common, preferred shares converted     260    
Preferred stock converted into common, common shares issued     167,743